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Despite major advances in the treatment of hematologi-
cal diseases over the last decades, allogeneic hematopoi-
etic stem cell transplantation (alloHSCT) still remains the 
only curative option for many of them. According to the 
recent survey of the European Society of Blood and Mar-
row Transplantation (EBMT), nearly 15 000 alloHSCT are 
currently performed each year across Europe and EBMT-
affiliated countries (1).
Approximately 50% of these patients will develop a major 
late complication – chronic graft-vs-host disease (cGVHD), 
a multi-organ allo- and auto-immune disorder affecting 
the skin, lungs, mouth, liver, eyes, joints, and gastrointes-
tinal and genital tracts (2-4). As a multisystem disease in 
these long-term survivors after alloHSCT, it presents with 
a number of heterogeneous clinical manifestations requir-
ing a multidisciplinary approach both in its diagnosis and 
treatment.
Chronic GVHD can last for many years causing severe 
medical, social, and quality of life problems, as well as sig-
nificantly impacting health-related costs and health care 
management. A recently published report from the Cen-
ter for International Blood and Marrow Transplant Research 
has identified a clear increase in the incidence of cGVHD 
from 1995 to 2007 due to the more frequent use of periph-
eral blood graft instead of bone marrow, unrelated donors, 
and older recipients (5). In addition, because of increasing 
safety of alloHSCT and better supportive care, there are 
more long-time survivors after alloHSCT and hence more 
patients are at risk of developing cGVHD (5).
cGVHD has been much better characterized using inter-
nationally recognized diagnostic criteria and scoring mea-
surements since the first National Institutes of Health (NIH) 
Consensus classification was developed in 2005 and pro-
spectively validated (3,6-10). However, there are still plenty 
of issues in addressing challenges posed by cGVHD to cli-
nicians and academic researchers. In June 2014, the sec-
ond cGVHD consensus conference was held at the Na-
tional Cancer Institute (NCI), NIH, USA, attended by 250 
participants from all over the world. A number of updated 
evidence-based recommendations were proposed at this 
conference and are detailed in the six new consensus pa-
pers published during 2015 in the Biology of Blood and 
Marrow Transplantation journal (4,11-15). These new rec-
ommendations should further advance cGVHD clinical re-
search related to diagnosis, staging, histopathology evalu-
ation, biomarkers, response criteria, design of clinical trials, 
estimating prognosis, guiding therapeutic decisions, an-
cillary and supportive care, as well as standardizing docu-
mentation.
The German-Austrian-Swiss cGVHD consortium assessed 
the usefulness of the NIH criteria in routine clinical prac-
tice and reported high rates of acceptance for definitions 
of cGVHD, as well as overall and organ-specific NIH cGVHD 
severity scoring among the vast majority of participants 
(16). An international survey of the EBMT-NCI cGVHD Task 
Force conducted in 2013 confirmed substantial national 
and international support for use of the NIH Consen-
sus criteria in everyday clinical practice (17). With the 
goal to implement the newest diagnostic criteria 
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and clinical standards for cGVHD in Croatia, a multidisci-
plinary clinical infrastructure for cGVHD was established 
at the University Hospital Center Zagreb in the middle of 
2013, supported by the Unity Through Knowledge Fund 
project entitled “Clinical and Biological Factors Determin-
ing Severity and Activity of Chronic Graft-Versus-Host Dis-
ease after Allogeneic Hematopoietic Stem Cell Transplan-
tation” funded by the World Bank and Croatian Ministry of 
Science, Education and Sports. Until now, 53 cGVHD pa-
tients have been prospectively evaluated in Zagreb by a 
multidisciplinary team of subspecialists in hematology, 
dermatology, dentistry, ophthalmology, physical therapy, 
pulmology, gynecology, nutrition, neurology, and other 
specialties when needed, with a collection of standardized 
demographic, clinical, laboratory, histopathology, and im-
aging data. Moreover, additional 43 transplanted patients 
without cGVHD were evaluated by Zagreb’s team to serve 
as controls. This approach improved the consistency of as-
sessment and treatment of patients with cGVHD and also 
validated the care-models and standards put forward by 
the internationally developed NIH criteria. This initiative is 
also playing a pivotal role in promoting interdisciplinary 
and international collaboration, stimulating education, ex-
change, and networking of researchers and clinicians, as 
well as the development of several scientific subprojects 
on this often devastating chronic disease.
Therefore, there has been significant research activity and 
renewed interest in cGVHD in the world over the last de-
cade. It is likely that the current better characterization of 
cGVHD, standardization of research tools, and numerous 
new treatment opportunities will lead to improved clinical 
outcomes, such as clinical symptoms, function status, qual-
ity of life, morbidity, and survival.
However, not a single agent has yet been approved for 
cGVHD prevention or treatment, neither by the US Food 
and Drug Administration (FDA) nor by the European Medi-
cines Agency (EMA). The current standard front-line steroid 
therapy has a 50% failure rate with significant toxicity, and 
there are no standards for second-line (and beyond) thera-
peutic options.
The focus now in this field is on further in-depth study 
of the biology of cGVHD, developing and validating new 
biomarkers, and pursuing clinical trials of new agents that 
would eventually develop pathways to their FDA and EMA 
regulatory approvals. The aim is to develop more effec-
tive, less toxic, and more targeted treatments that will 
not interfere with the beneficial graft-vs-tumor ef-
fects. To advance this field and break the 30-year-old sub-
optimal treatment paradigms, the goal is that each cGVHD 
patient should be either treated in a clinical trial or at least 
should be documented within a registry capturing essen-
tial clinical data on the course of cGVHD. The tools and op-
portunities to harness cGVHD and create better and saf-
er alloHSCT are in our hands right now. This issue of the 
Croatian Medical Journal presents several excellent articles 
that are a product of these enhanced international col-
laborations and efforts by teams across Europe to address 
cGVHD.
Acknowledgment This work is supported by the Unity Through Knowl-
edge Fund project entitled “Clinical and Biological Factors Determining 
Severity and Activity of Chronic Graft-Versus-Host Disease after Allogeneic 
Hematopoietic Stem Cell Transplantation.” The opinions expressed here are 
those of the authors and do not represent the official position of the Na-
tional Institutes of Health or the US Government.
References
1 Passweg JR, Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P, et 
al. Hematopoietic SCT in Europe 2013: recent trends in the use of 
alternative donors showing more haploidentical donors but fewer 
cord blood transplants. Bone Marrow Transplant. 2015;50:476-82. 
Medline:25642761 doi:10.1038/bmt.2014.312
2 Baird K, Pavletic SZ. Chronic graft versus host disease. Curr Opin 
Hematol. 2006;13:426-35. Medline:17053454 doi:10.1097/01.
moh.0000245689.47333.ff
3 Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, 
et al. National Institutes of Health consensus development project 
on criteria for clinical trials in chronic graft-versus-host disease: I. 
Diagnosis and Staging Working Group report. Biol Blood Marrow 
Transplant. 2005;11:945-56. Medline:16338616 doi:10.1016/j.
bbmt.2005.09.004
4 Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, 
et al. National Institutes of Health consensus development project 
on criteria for clinical trials in chronic graft-versus-host disease: 
I. The 2014 Diagnosis and Staging Working Group Report. Biol 
Blood Marrow Transplant. 2015;21:389-401. Medline:25529383 
doi:10.1016/j.bbmt.2014.12.001
5 Arai S, Arora M, Wang T, Spellman SR, He W, Couriel DR, et 
al. Increasing incidence of chronic graft-versus-host disease 
in allogeneic transplantation: a report from the Center for 
International Blood and Marrow Transplant Research. Biol 
Blood Marrow Transplant. 2015;21:266-74. Medline:25445023 
doi:10.1016/j.bbmt.2014.10.021
6 Shulman HM, Kleiner D, Lee SJ, Morton T, Pavletic SZ, Farmer E, et 
al. Histopathologic diagnosis of chronic graft-versus-host disease: 
National Institutes of Health consensus development project on 
criteria for clinical trials in chronic graft-versus-host disease: II. 
Pathology Working Group report. Biol Blood Marrow Transplant. 
2006;12:31-47. Medline:16399567 doi:10.1016/j.bbmt.2005.10.023
3Pulanić et al: Chronic graft-vs-host disease in 2016
www.cmj.hr
7 Schultz KR, Miklos DB, Fowler D, Cooke K, Shizuru J, Zorn E, et al. 
Toward biomarkers for chronic graft-versus-host disease: National 
Institutes of Health consensus development project on criteria 
for clinical trials in chronic graft versus-host disease: III. Biomarker 
Working Group report. Biol Blood Marrow Transplant. 2006;12:126-
37. Medline:16443511 doi:10.1016/j.bbmt.2005.11.010
8 Pavletic SZ, Martin P, Lee SJ, Mitchell S, Jacobsohn D, Cowen EW, 
et al; Response Criteria Working Group. Measuring therapeutic 
response in chronic graft-versus-host disease: National Institutes of 
Health consensus development project on criteria for clinical trials 
in chronic graft-versus-host disease: IV. Response Criteria Working 
Group report. Biol Blood Marrow Transplant. 2006;12:252-66. 
Medline:16503494 doi:10.1016/j.bbmt.2006.01.008
9 Couriel D, Carpenter PA, Cutler C, Bolańos-Meade J, Treister 
NS, Gea-Banacloche J, et al. Ancillary therapy and supportive 
care of chronic graft-versus-host disease: National Institutes of 
Health consensus development project on criteria for clinical 
trials in chronic graft-versus-host disease: V. Ancillary Therapy 
and Supportive Care Working Group Report. Biol Blood Marrow 
Transplant. 2006;12:375-96. Medline:16545722 doi:10.1016/j.
bbmt.2006.02.003
10 Martin PJ, Weisdorf D, Przepiorka D, Hirschfeld S, Farrell A, Rizzo JD, 
et al; Design of Clinical Trials Working Group. National Institutes of 
Health consensus development project on criteria for clinical trials 
in chronic graft-versus-host disease: VI. Design of Clinical Trials 
Working Group report. Biol Blood Marrow Transplant. 2006;12:491-
505. Medline:16635784 doi:10.1016/j.bbmt.2006.03.004
11 Shulman HM, Cardona DM, Greenson JK, Hingorani S, Horn T, 
Huber E, et al. NIH Consensus Development Project on Criteria 
for Clinical Trials in Chronic Graft-versus-Host Disease: II. The 
2014 Pathology Working Group Report. Biol Blood Marrow 
Transplant. 2015;21:589-603. Medline:25639770 doi:10.1016/j.
bbmt.2014.12.031
12 Paczesny S, Hakim FT, Pidala J, Cooke K, Lathrop J, Griffith LM, et 
al. National Institutes of Health Consensus Development Project 
on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: 
III. The 2014 Biomarker Working Group Report. Biol Blood Marrow 
Transplant. 2015;21:780-92. Medline:25644957 doi:10.1016/j.
bbmt.2015.01.003
13 Lee SJ, Wolff D, Kitko C, Koreth J, Inamoto Y, Jagasia M, et al. 
Measuring therapeutic response in chronic graft-versus-host 
disease. National Institutes of Health Consensus Development 
Project on Criteria for Clinical Trials in Chronic Graft-versus-Host 
Disease: IV. The 2014 Response Criteria Working Group Report. 
Biol Blood Marrow Transplant. 2015;21:984-99. Medline:25796139 
doi:10.1016/j.bbmt.2015.02.025
14 Carpenter PA, Kitko CL, Elad S, Flowers MED, Gea-Banacloche 
JC, Halter JP, et al. National Institutes of Health Consensus 
Development Project on Criteria for Clinical Trials in Chronic 
Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and 
Supportive Care Working Group Report. Biol Blood Marrow 
Transplant. 2015;21:1167-87. Medline:25838185 doi:10.1016/j.
bbmt.2015.03.024
15 Martin PJ, Lee SJ, Przepiorka D, Horowitz MM, Koreth J, Vogelsang 
GB, et al. National Institutes of Health Consensus Development 
Project on Criteria for Clinical Trials in Chronic Graft-versus-Host 
Disease: VI. The 2014 Clinical Trial Design Working Group Report. 
Biol Blood Marrow Transplant. 2015;21:1343-59. Medline:25985921
16 Greinix HT, Loddenkemper C, Pavletic SZ, Holler E, Socie G, 
Lawitschka A, et al. Diagnosis and staging of chronic graft-
versus-host disease in the clinical practice. Biol Blood Marrow 
Transplant. 2011;17:167-75. Medline:20691801 doi:10.1016/j.
bbmt.2010.07.017
17 Duarte RF, Greinix H, Rabin B, Mitchell SA, Basak G, Wolff D, et al. 
Uptake and use of recommendations for the diagnosis, severity 
scoring and management of chronic GVHD: an international 
survey of the EBMT-NCI Chronic GVHD Task Force. Bone Marrow 
Transplant. 2014;49:49-54. Medline:23955633 doi:10.1038/
bmt.2013.129
